# LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

> **NCT07288398** · PHASE3 · RECRUITING · sponsor: **Tenax Therapeutics, Inc.** · enrollment: 540 (estimated)

## Conditions studied

- Pulmonary Hypertension Associated With HFpEF

## Interventions

- **DRUG:** TNX-103
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07288398
- **Lead sponsor:** Tenax Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288398, "LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07288398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*